Jefferies Financial Group’s LENZ Therapeutics LENZ Stock Holding History

Jefferies Financial Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	+200,300	New	+$1.61M	0.01%	915

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Jefferies Financial Group's LENZ Position: Q2 2026 in Review

Jefferies Financial Group opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 200,300 shares worth $1.14M. The stake represents 0.01% of the portfolio and ranks #915 among its holdings.

144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Jefferies Financial Group held 200,300 shares of LENZ Therapeutics worth $1.14M as of Q2 2026.
LENZ Therapeutics was a new Jefferies Financial Group position in Q2 2026.
LENZ Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #915 holding.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.